Provided by Tiger Trade Technology Pte. Ltd.

Telix Pharmaceuticals Ltd. (Uplisting)

11.45
+0.60005.53%
Pre-market: 11.750.3000+2.62%05:14 EDT
Volume:239.37K
Turnover:2.75M
Market Cap:3.88B
PE:120.04
High:11.79
Open:11.40
Low:11.38
Close:10.85
52wk High:12.48
52wk Low:6.28
Shares:339.00M
Float Shares:272.00M
Volume Ratio:2.02
T/O Rate:0.09%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.0954
EPS(LYR):-0.0211
ROE:7.36%
ROA:2.71%
PB:7.96
PE(LYR):-542.65

Loading ...

Telix Pharmaceuticals Issues New Tranche of Unquoted Convertible Notes

TIPRANKS
·
Apr 23

ProstACT Global Phase 3 (Part 1) Selected as Late-Breaking Abstract at ASCO 2026

GlobeNewswire
·
Apr 22

Assessing Telix Pharmaceuticals (ASX:TLX) Valuation After Regeneron Deal And Phase 3 IPAX BrIGHT Launch

Simply Wall St.
·
Apr 21

Telix Pharmaceuticals Becomes Most Shorted ASX Stock as of April 15, ASIC Data Shows

MT Newswires Live
·
Apr 21

Telix Sets Hybrid 2026 AGM to Engage Global Investor Base

TIPRANKS
·
Apr 21

Telix raises US$600m via new convertible notes to refinance 2029 bonds

TIPRANKS
·
Apr 20

Telix Pharmaceuticals Says JPMorgan Increases Stake

MT Newswires Live
·
Apr 17

Canaccord Genuity Keeps Their Buy Rating on Telix Pharmaceuticals (TLPPF)

TIPRANKS
·
Apr 17

Telix Issues New Unquoted Share Rights Under Employee Incentive Scheme

TIPRANKS
·
Apr 16

Analysts Offer Insights on Healthcare Companies: AbCellera Biologics (ABCL), Telix Pharmaceuticals (OtherTLPPF) and Johnson & Johnson (JNJ)

TIPRANKS
·
Apr 15

Telix Pharmaceuticals Doses First Patient in Phase 3 Brain Cancer Trial

MT Newswires Live
·
Apr 15

Telix Pharmaceuticals Files Appendix 3B for Proposed Securities Issue

TIPRANKS
·
Apr 15

Telix Doses First Patient in Phase 3 IPAX-BrIGHT Trial of TLX101-Tx for Recurrent Glioblastoma

prnewswire
·
Apr 15

Top Premarket Decliners

MT Newswires Live
·
Apr 14

Telix Refinances Convertible Bonds

prnewswire
·
Apr 14

Telix Showcases Glioblastoma Case Response and Details Offshore Convertible Bond Offer

TIPRANKS
·
Apr 14

Telix Raises US$550m in Convertible Note Refi to Extend Debt Maturity

TIPRANKS
·
Apr 14

Telix Pharmaceuticals Price Target Maintained With a $20.00/Share by HC Wainwright & Co.

Dow Jones
·
Apr 13

Telix and Regeneron Strike Global Radiopharma Alliance in Precision Oncology Push

TIPRANKS
·
Apr 13

Telix and Regeneron Announce Strategic Radiopharma Collaboration

prnewswire
·
Apr 13